MDAI vs. BWAY, BLUA, KRMD, SRTS, HSAQ, ALUR, PDEX, NVNO, MGRM, and NSPR
Should you be buying Spectral AI stock or one of its competitors? The main competitors of Spectral AI include BrainsWay (BWAY), BlueRiver Acquisition (BLUA), KORU Medical Systems (KRMD), Sensus Healthcare (SRTS), Health Sciences Acquisitions Co. 2 (HSAQ), Allurion Technologies (ALUR), Pro-Dex (PDEX), enVVeno Medical (NVNO), Monogram Orthopaedics (MGRM), and InspireMD (NSPR). These companies are all part of the "surgical & medical instruments" industry.
Spectral AI (NASDAQ:MDAI) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, community ranking, analyst recommendations and valuation.
Spectral AI has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.
BrainsWay has higher revenue and earnings than Spectral AI.
BrainsWay received 61 more outperform votes than Spectral AI when rated by MarketBeat users. However, 100.00% of users gave Spectral AI an outperform vote while only 64.58% of users gave BrainsWay an outperform vote.
In the previous week, Spectral AI had 2 more articles in the media than BrainsWay. MarketBeat recorded 6 mentions for Spectral AI and 4 mentions for BrainsWay. BrainsWay's average media sentiment score of 1.53 beat Spectral AI's score of 0.51 indicating that BrainsWay is being referred to more favorably in the news media.
Spectral AI has a net margin of 0.00% compared to BrainsWay's net margin of -4.83%. Spectral AI's return on equity of 0.00% beat BrainsWay's return on equity.
67.1% of Spectral AI shares are held by institutional investors. Comparatively, 30.1% of BrainsWay shares are held by institutional investors. 56.7% of Spectral AI shares are held by insiders. Comparatively, 19.0% of BrainsWay shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Spectral AI presently has a consensus target price of $4.00, suggesting a potential upside of 140.96%. BrainsWay has a consensus target price of $13.00, suggesting a potential upside of 106.68%. Given Spectral AI's stronger consensus rating and higher possible upside, equities analysts plainly believe Spectral AI is more favorable than BrainsWay.
Summary
Spectral AI and BrainsWay tied by winning 8 of the 16 factors compared between the two stocks.
Get Spectral AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for MDAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MDAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spectral AI Competitors List
Related Companies and Tools
